{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:15:09Z","timestamp":1778771709424,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is no explicitly normal or abnormal level of prostate specific antigen (PSA) in the blood, yet the lab reported \u201cupper limit of normal\u201d (ULN) represents the most accessible guidance available to physicians interpreting these tests and is agnostic to risk factors and life expectancy. We hypothesize that \u201cabnormal flagging\u201d on \u201celevated\u201d results is a potent driver of downstream care irrespective of a patient\u2019s underlying prostate cancer risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Regression discontinuity design was applied to a cohort of patients undergoing PSA screening at a single center to isolate and estimate the impact of \u201cabnormal flagging\u201d of results above the PSA ULN on subsequent early repeat (\u201cconfirmatory\u201d) PSA testing, urology referral, and prostate MRI or biopsy (or both).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Amongst 38,042 screening PSA tests, 1041 (2.7%) were flagged as abnormal. Adjusting for patient age and PSA gap, \u201cabnormal\u201d flagging of PSA (versus \u201cnormal\u201d) was associated with an increased odds of repeat PSA testing (OR: 14.17; 95% CI 11.53\u201317.43;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), referral (odds ratio (OR): 10.03; 95% confidence interval (CI) 7.53\u201313.47;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and either prostate MRI or biopsy (or both; OR 13.61; 95% CI 8.81\u201321.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the use of PSA ULN has recognized shortcomings, abnormal flagging of results above this threshold strongly influences additional testing, referral, and biopsy, potentially leading to risk-discordant over- and under-evaluation. An improved reporting standard may include risk estimates of meaningful endpoints such as the risk of prostate cancer metastasis or death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-10075-x","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T18:28:05Z","timestamp":1765304885000},"page":"1743-1749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abnormal Flagging of Prostate Specific Antigen Screening Tests: A Regression Discontinuity Design"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0692-2909","authenticated-orcid":false,"given":"Patrick","family":"Lewicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Stensland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"1","key":"10075_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaoncol.2021.5143","volume":"8","author":"MS Leapman","year":"2022","unstructured":"Leapman MS, Wang R, Park H, et al. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncol. 2022;8(1):41-47. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5143.","journal-title":"JAMA Oncol."},{"key":"10075_CR2","doi-asserted-by":"publisher","unstructured":"Sundaresan VM, Smani S, Rajwa P, et al. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol. Published online July 16, 2024:S1078\u20131439(24)00505\u20132. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.003.","DOI":"10.1016\/j.urolonc.2024.06.003"},{"issue":"7","key":"10075_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/jama.1993.03510070082041","volume":"270","author":"JE Oesterling","year":"1993","unstructured":"Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860-864.","journal-title":"JAMA."},{"issue":"7","key":"10075_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jamaoncol.2015.2993","volume":"1","author":"J Shoag","year":"2015","unstructured":"Shoag J, Halpern J, Eisner B, et al. Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial. JAMA Oncol. 2015;1(7):984-986. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2993.","journal-title":"JAMA Oncol."},{"issue":"1","key":"10075_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023;210(1):46-53. https:\/\/doi.org\/10.1097\/JU.0000000000003491.","journal-title":"J Urol."},{"issue":"13","key":"10075_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. New England J Med. 2009;360(13):1320-1328. https:\/\/doi.org\/10.1056\/NEJMoa0810084.","journal-title":"New England J Med."},{"issue":"4","key":"10075_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/jama.2020.3822","volume":"324","author":"ML Maciejewski","year":"2020","unstructured":"Maciejewski ML, Basu A. Regression Discontinuity Design. JAMA. 2020;324(4):381-382. https:\/\/doi.org\/10.1001\/jama.2020.3822.","journal-title":"JAMA."},{"key":"10075_CR8","doi-asserted-by":"publisher","first-page":"e2400261","DOI":"10.1200\/CCI-24-00261","volume":"9","author":"P Lewicki","year":"2025","unstructured":"Lewicki P, Benhalim Y, Bradin J, et al. Development and Evaluation of an Electronic Health Record-Derived Computable Phenotype to Identify Patients Undergoing Prostate Cancer Screening. JCO Clin Cancer Inform. 2025;9:e2400261. https:\/\/doi.org\/10.1200\/CCI-24-00261.","journal-title":"JCO Clin Cancer Inform."},{"issue":"5","key":"10075_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/EDE.0000000000000138","volume":"25","author":"J Bor","year":"2014","unstructured":"Bor J, Moscoe E, Mutevedzi P, Newell ML, B\u00e4rnighausen T. Regression discontinuity designs in epidemiology: causal inference without randomized trials. Epidemiology. 2014;25(5):729-737. https:\/\/doi.org\/10.1097\/EDE.0000000000000138.","journal-title":"Epidemiology."},{"issue":"2","key":"10075_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, Straubinger J, Selig K, et al. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol. 2018;74(2):197-203. https:\/\/doi.org\/10.1016\/j.eururo.2018.05.003.","journal-title":"Eur Urol."},{"issue":"6","key":"10075_CR11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83(6):1362-1367. https:\/\/doi.org\/10.1016\/j.urology.2014.02.035.","journal-title":"Urology."},{"issue":"2","key":"10075_CR12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jeconom.2007.05.005","volume":"142","author":"J McCrary","year":"2008","unstructured":"McCrary J. Manipulation of the running variable in the regression discontinuity design: A density test. Journal of Econometrics. 2008;142(2):698-714. https:\/\/doi.org\/10.1016\/j.jeconom.2007.05.005.","journal-title":"J Econ."},{"issue":"1117","key":"10075_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/postgradmedj-2018-135983","volume":"94","author":"MB Whyte","year":"2018","unstructured":"Whyte MB, Kelly P. The normal range: it is not normal and it is not a range. Postgrad Med J. 2018;94(1117):613-616. https:\/\/doi.org\/10.1136\/postgradmedj-2018-135983.","journal-title":"Postgrad Med J."},{"issue":"1","key":"10075_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/aja.2009.9","volume":"12","author":"JC Boyd","year":"2010","unstructured":"Boyd JC. Defining laboratory reference values and decision limits: populations, intervals, and interpretations. Asian J Androl. 2010;12(1):83-90. https:\/\/doi.org\/10.1038\/aja.2009.9.","journal-title":"Asian J Androl."},{"issue":"1","key":"10075_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, et al.\u00a0A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009.","journal-title":"Eur Urol."},{"issue":"5","key":"10075_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1056\/NEJM199608013350502","volume":"335","author":"TO Morgan","year":"1996","unstructured":"Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men. New England J Med. 1996;335(5):304-310. https:\/\/doi.org\/10.1056\/NEJM199608013350502.","journal-title":"New England J Med."},{"issue":"6","key":"10075_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0090-4295(00)00517-3","volume":"55","author":"HB Carter","year":"2000","unstructured":"Carter HB. A PSA threshold of 4.0 ng\/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. Urology. 2000;55(6):796-799. https:\/\/doi.org\/10.1016\/S0090-4295(00)00517-3.","journal-title":"Urology."},{"issue":"6 Suppl","key":"10075_CR18","doi-asserted-by":"publisher","first-page":"273S","DOI":"10.1016\/s0197-2456(00)00098-2","volume":"21","author":"PC Prorok","year":"2000","unstructured":"Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):273S-309S. https:\/\/doi.org\/10.1016\/s0197-2456(00)00098-2.","journal-title":"Control Clin Trials."},{"issue":"10","key":"10075_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England J Med. 2020;382(10):917-928. https:\/\/doi.org\/10.1056\/NEJMoa1910038.","journal-title":"New England J Med."},{"key":"10075_CR20","doi-asserted-by":"publisher","unstructured":"Carlsson SV, Carroll PR, Hamdy FC. Reevaluating the Definition of Clinically Significant Prostate Cancer as Grade Groups 2 to 5: An Imperative for Improved Risk Stratification. The Journal of Urology. Published online February 2025. https:\/\/doi.org\/10.1097\/JU.0000000000004253.","DOI":"10.1097\/JU.0000000000004253"},{"issue":"23","key":"10075_CR21","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1002\/cncr.34981","volume":"129","author":"CD Gaffney","year":"2023","unstructured":"Gaffney CD, Tin AL, Fainberg J, et al. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy. Cancer. 2023;129(23):3790-3796. https:\/\/doi.org\/10.1002\/cncr.34981.","journal-title":"Cancer."},{"issue":"23","key":"10075_CR22","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1001\/jama.2024.20580","volume":"332","author":"I Ajjawi","year":"2024","unstructured":"Ajjawi I, Loeb S, Cooperberg MR, et al. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA. 2024;332(23):2033-2036. https:\/\/doi.org\/10.1001\/jama.2024.20580.","journal-title":"JAMA."},{"issue":"17","key":"10075_CR23","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","volume":"331","author":"A Auvinen","year":"2024","unstructured":"Auvinen A, Tammela TLJ, Mirtti T, et al. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA. 2024;331(17):1452-1459. https:\/\/doi.org\/10.1001\/jama.2024.3841.","journal-title":"JAMA."},{"issue":"12","key":"10075_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","volume":"391","author":"J Hugosson","year":"2024","unstructured":"Hugosson J, Godtman RA, Wallstrom J, et al. Results after Four Years of Screening for Prostate Cancer with PSA and MRI. New England J Med. 2024;391(12):1083-1095. https:\/\/doi.org\/10.1056\/NEJMoa2406050.","journal-title":"New England J Med."},{"issue":"22","key":"10075_CR25","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246. https:\/\/doi.org\/10.1056\/NEJMoa031918.","journal-title":"N Engl J Med."},{"issue":"3","key":"10075_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/MED.0b013e328360332a","volume":"20","author":"L Klotz","year":"2013","unstructured":"Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diab Obes. 2013;20(3):204. https:\/\/doi.org\/10.1097\/MED.0b013e328360332a.","journal-title":"Curr Opin Endocrinol Diab Obes."},{"key":"10075_CR27","doi-asserted-by":"publisher","first-page":"215013192110697","DOI":"10.1177\/21501319211069756","volume":"13","author":"K Clift","year":"2022","unstructured":"Clift K, Macklin-Mantia S, Barnhorst M, et al. Comparison of a Focused Family Cancer History Questionnaire to Family History Documentation in the Electronic Medical Record. J Prim Care Community Health. 2022;13:21501319211069756. https:\/\/doi.org\/10.1177\/21501319211069756.","journal-title":"J Prim Care Community Health."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-10075-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:50:21Z","timestamp":1778770221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-10075-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10075"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-10075-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS is a consultant for Innovative Analytics. TM is an advisory board member for A3P Biosciences and Foundation Medicine. Other authors have none to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}